زراعة القلب

What is Orthotopic Heart Transplantation?

For end-stage heart failure refractory to medical therapy and device support, heart transplantation remains the definitive treatment. 1-year survival now exceeds 90% at experienced centers with excellent long-term quality of life.

Why China?

• Fuwai + Wuhan Union: Asia's top heart transplant programs — 100+ transplants/year
• Cost: $80,000-$140,000 (transplant + 1st year) vs. $1.2-$1.8M in the US
• Shorter waitlist: 6-12 months vs 12-24 months in many Western countries
• LVAD bridging: HeartMate 3, HeartWare, and Chinese-developed CH-VAD available

Who is a candidate?

• End-stage heart failure (INTERMACS 1-3)
• Refractory to optimal medical therapy
• Age <70 (expanded criteria in select cases)
• No significant pulmonary hypertension
• Acceptable psychosocial support

Outcomes

1-year survival: 90%+. 5-year survival: 75-80%. 10-year survival: 55-65%. Freedom from cardiac allograft vasculopathy at 5 years: 70-80%. Quality of life returning to near-normal in 80%+ of recipients.